This document summarizes Invitae Corporation's fourth quarter and full-year 2017 financial results. It discusses Invitae's rapid growth in 2017, with over 150,000 samples accessioned representing 154% year-over-year volume growth and $68.2 million in revenue representing 172% growth. Invitae achieved a gross profit of $18.1 million for the full year. The document also provides details on Invitae's balance sheet, cash position, acquisitions, and strategy for continued growth.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
This document brings together a set of latest data points and publicly available information relevant for Healthcare Industry. We are very excited to share this content and believe that readers will benefit from this periodic publication immensely.
BioCentury BayHelix China healthcare Summit 2016 - McKinsey report _building...Franck Le Deu
In this report prepared in the context of the BioCentury China Summit, we provide an overview of the latest trends impacting China healthcare and the biopharma market, including the CFDA reform.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
This document brings together a set of latest data points and publicly available information relevant for Healthcare Industry. We are very excited to share this content and believe that readers will benefit from this periodic publication immensely.
BioCentury BayHelix China healthcare Summit 2016 - McKinsey report _building...Franck Le Deu
In this report prepared in the context of the BioCentury China Summit, we provide an overview of the latest trends impacting China healthcare and the biopharma market, including the CFDA reform.
To manufacture and provide the customers with quality products to the best interest of the customers.
To create Price competitive Products as part of the effect to increase the world access to high-quality chocolates.
To ensure a hygienic & clean working environment as to continue to produce Safe & Tasty Products
To strive to Meet & Exceed Customer's Expectations so as to ensure a sustainable business relationship.
The chocolate market is estimated at around 33,000 tonnes valued at approximately Rs. 8 billion. Bars of molded chocolates like aAmul milk chocolate, dairy milk, truffle, nestle premium and nestle milky bar comprise the largest segment, accounting for 37% of the total market in terms of volume. To push sales chocolate companies have been targeting mainly adult audiences. Chocolates are being presented as snack food for the new target audiences. The chocolate segment is characterized by high volumes, huge expenses on advertising, low margins, and price sensitivity
Cadbury is the leading player in the chocolate market industry with a penetration of 70% market share. The company's brands like Five Star, Gems, Éclairs, Perk, and Dairy Milk are leaders in their segments. Nestle & Amul are the other major players in the chocolate industry. Chocolate industry is growing at steady growth rate of 25%. Over 70% of the consumption of chocolates takes place in the urban market. It is price sensitive market.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Management presentation from Thermal Energy International's 2017 Annual General Meeting of Shareholders. Provides highlights of recent growth initiatives and the growth strategy going forward.
StartUp Health’s Annual Insights Report: The Year Digital Health Hit its Stri...Jill Gilbert
2017 is on track to be the biggest year yet for digital health funding, with almost $2.4B in deals in Q3 alone, according to StartUp Health Insights’ 2016 Q3 Report. With a record quarter on the books and no signs of funding slowing down, join the Director of StartUp Health Academy as she shares the latest market trends and advances in digital health technology and what’s in store over the next quarter, next year, and 10+ years from now.
In today’s healthcare market, financial challenges rank as the number one issue hospitals face. To maintain a margin to support their mission, hospital CEOs must always be on the lookout for opportunities to boost revenue through improved reimbursement. In this webinar, Thibodaux Regional Medical Center’s Greg Stock, president and chief executive officer, and Mikki Fazzio, director, HIM and clinical documentation improvement, as they share how Thibodaux Regional leveraged analytics to provide actionable feedback to continuously improve the process, and how you can too.
Managing ‘discharged not final billed’ (DNFB) cases is one important way hospitals can improve financial performance by increasing collection on bills with incomplete payment due to coding or documentation gaps. Historically, Thibodaux Regional’s DNFB caseload had reached 500 cases per month, with about a third of patients discharged without a completed bill due either to missing documentation or incomplete coding. Thibodaux Regional tackled this process problem by expanding the use of analytics to measure and track every aspect of their billing services. The results were impressive and sustainable. Three years after launching its initial DNFB redesign effort, Thibodaux Regional has realized $2.4M in additional annual reimbursement and a 61% relative reduction in DNFB dollars, as well as a 6.2 reduction in AR days, resulting in significantly improved cash flow.
View this webinar to learn how to:
- Increase reimbursement levels by optimizing workflow analytics
- Ease the documentation burden on overloaded physicians with time-efficient communication
- Provide critical analytics visibility to key stakeholders
3. Bring comprehensive genetic information into mainstream
medical practice to improve the quality of healthcare for
billions of people
Genetic information is
more valuable when
shared
Driving down the cost of
genetic information will
increase its personal and
clinical utility
Healthcare professionals
are fundamental in
ordering and interpreting
genetic information
People should own and
control their own
genetic information
Core principles